Literature DB >> 9208282

Protein kinase C beta II isoform is up-regulated in human proliferative glomerulonephritis.

M B Ganz1, R Abu-Nader, R Saxena, J Grond.   

Abstract

Cell proliferation is a predominant feature in glomerulonephritis (GN). Recent work has suggested that protein kinase C (PKC) isoforms are responsible, specifically, PKC beta II in part, for cell growth. PKC beta II is expressed during cell growth in early glomerulogenesis and inflammatory mediators of glomerular disease induce PKC beta II expression. We therefore investigated the expression of PKC beta II in kidney biopsy specimens from patients with various types of proliferative (n = 41), nonproliferative GN (n = 23), and in structurally normal kidneys (n = 15). PKC beta II immunoreactivity was exclusively found in proliferative GN whereas PKC expression was not detected in normal glomerular and in nonproliferative disease states. The consistent expression of PKC beta II in proliferative GN suggests a key signaling role for this enzyme in cell proliferation in renal disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208282

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  3 in total

1.  Significance and expression of serum and glucocorticoid-inducible kinase in kidney of mice with diabetic nephropathy.

Authors:  Quansheng Wang; Xiaoli Zhang; Yumei Wang; Anguo Deng; Zhonghua Zhu; Yuxi Feng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

2.  Expression of Ser729 phosphorylated PKCepsilon in experimental crescentic glomerulonephritis: an immunohistochemical study.

Authors:  V N Karavana; H Gakiopoulou; E A Lianos
Journal:  Eur J Histochem       Date:  2014-04-15       Impact factor: 3.188

3.  Inhibition of TRPC6 by protein kinase C isoforms in cultured human podocytes.

Authors:  Lídia Ambrus; Attila Oláh; Tamás Oláh; György Balla; Moin A Saleem; Petronella Orosz; Judit Zsuga; Klára Bíró; László Csernoch; Tamás Bíró; Tamás Szabó
Journal:  J Cell Mol Med       Date:  2015-09-25       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.